These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 24970912)

  • 1. A tyrosine kinase inhibitor-based high-affinity PET radiopharmaceutical targets vascular endothelial growth factor receptor.
    Li F; Jiang S; Zu Y; Lee DY; Li Z
    J Nucl Med; 2014 Sep; 55(9):1525-31. PubMed ID: 24970912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positron emission tomography imaging and biodistribution of vascular endothelial growth factor with 64Cu-labeled bevacizumab in colorectal cancer xenografts.
    Paudyal B; Paudyal P; Oriuchi N; Hanaoka H; Tominaga H; Endo K
    Cancer Sci; 2011 Jan; 102(1):117-21. PubMed ID: 21070475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A vascular endothelial growth factor 121 (VEGF(121))-based dual PET/optical probe for in vivo imaging of VEGF receptor expression.
    Kang CM; Koo HJ; Lee KC; Choe YS; Choi JY; Lee KH; Kim BT
    Biomaterials; 2013 Sep; 34(28):6839-45. PubMed ID: 23787114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PET of vascular endothelial growth factor receptor expression.
    Cai W; Chen K; Mohamedali KA; Cao Q; Gambhir SS; Rosenblum MG; Chen X
    J Nucl Med; 2006 Dec; 47(12):2048-56. PubMed ID: 17138749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo small-animal PET/CT of EphB4 receptors using 64Cu-labeled peptide.
    Xiong C; Huang M; Zhang R; Song S; Lu W; Flores L; Gelovani J; Li C
    J Nucl Med; 2011 Feb; 52(2):241-8. PubMed ID: 21233177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new PET tracer specific for vascular endothelial growth factor receptor 2.
    Wang H; Cai W; Chen K; Li ZB; Kashefi A; He L; Chen X
    Eur J Nucl Med Mol Imaging; 2007 Dec; 34(12):2001-10. PubMed ID: 17694307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PET Imaging of VEGFR-2 Expression in Lung Cancer with 64Cu-Labeled Ramucirumab.
    Luo H; England CG; Graves SA; Sun H; Liu G; Nickles RJ; Cai W
    J Nucl Med; 2016 Feb; 57(2):285-90. PubMed ID: 26541778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and evaluation of 64Cu-labeled monomeric and dimeric NGR peptides for MicroPET imaging of CD13 receptor expression.
    Chen K; Ma W; Li G; Wang J; Yang W; Yap LP; Hughes LD; Park R; Conti PS
    Mol Pharm; 2013 Jan; 10(1):417-27. PubMed ID: 23190134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PET Imaging of HER2-Positive Tumors with Cu-64-Labeled Affibody Molecules.
    Qi S; Hoppmann S; Xu Y; Cheng Z
    Mol Imaging Biol; 2019 Oct; 21(5):907-916. PubMed ID: 30617730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small-animal PET imaging of human epidermal growth factor receptor positive tumor with a 64Cu labeled affibody protein.
    Miao Z; Ren G; Liu H; Jiang L; Cheng Z
    Bioconjug Chem; 2010 May; 21(5):947-54. PubMed ID: 20402512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative PET imaging of VEGF receptor expression.
    Chen K; Cai W; Li ZB; Wang H; Chen X
    Mol Imaging Biol; 2009; 11(1):15-22. PubMed ID: 18784964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PET imaging of insulin-like growth factor type 1 receptor expression with a 64Cu-labeled Affibody molecule.
    Su X; Cheng K; Liu Y; Hu X; Meng S; Cheng Z
    Amino Acids; 2015 Jul; 47(7):1409-19. PubMed ID: 25854877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of 64Cu- and 125I-radiolabeled bitistatin as potential agents for targeting alpha v beta 3 integrins in tumor angiogenesis.
    McQuade P; Knight LC; Welch MJ
    Bioconjug Chem; 2004; 15(5):988-96. PubMed ID: 15366951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a Radiolabeled Irreversible Peptide Ligand for PET Imaging of Vascular Endothelial Growth Factor.
    Marquez BV; Ikotun OF; Parry JJ; Rogers BE; Meares CF; Lapi SE
    J Nucl Med; 2014 Jun; 55(6):1029-34. PubMed ID: 24732153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of (64)Cu-labeled DOTA-D-Phe(1)-Tyr (3)-octreotide ((64)Cu-DOTA-TOC) for imaging somatostatin receptor-expressing tumors.
    Hanaoka H; Tominaga H; Yamada K; Paudyal P; Iida Y; Watanabe S; Paudyal B; Higuchi T; Oriuchi N; Endo K
    Ann Nucl Med; 2009 Aug; 23(6):559-67. PubMed ID: 19504168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dosimetry of 64Cu-DOTA-AE105, a PET tracer for uPAR imaging.
    Persson M; El Ali HH; Binderup T; Pfeifer A; Madsen J; Rasmussen P; Kjaer A
    Nucl Med Biol; 2014 Mar; 41(3):290-5. PubMed ID: 24533988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and comparative evaluation of novel (64)Cu-labeled high affinity cell-specific peptides for positron emission tomography imaging of tumor vasculature.
    Merrill JR; Krajewski K; Yuan H; Frank JE; Lalush DS; Patterson C; Veleva AN
    Biomaterials; 2016 Apr; 84():241-249. PubMed ID: 26839954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New affinity probe targeting VEGF receptors for kinase inhibitor selectivity profiling by chemical proteomics.
    Ku X; Heinzlmeir S; Helm D; Médard G; Kuster B
    J Proteome Res; 2014 May; 13(5):2445-52. PubMed ID: 24712744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective Imaging of VEGFR-1 and VEGFR-2 Using 89Zr-Labeled Single-Chain VEGF Mutants.
    Meyer JP; Edwards KJ; Kozlowski P; Backer MV; Backer JM; Lewis JS
    J Nucl Med; 2016 Nov; 57(11):1811-1816. PubMed ID: 27390161
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.